Merck has completed its acquisition of Exelead for $780 million. The company specializes in the development and production of complex injectable drugs and lipid nanoparticle-based drug delivery technologies, which is key in the mRNA therapy of Covid-19 and many other diseases.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept